AstraZeneca-Bristol Myers Deal Could Unlock $400 Billion in Cost Savings

Mizuho Securities' healthcare sector specialist Jared Holz has made a strong case for AstraZeneca's potential acquisition of Bristol Myers Squibb. He argues that combining these two companies could result in significant cost savings, potentially reaching $400 billion.

Holz highlighted the existing $2 billion cost-savings program at Bristol Myers and its discounted forward P/E ratio of approximately 10 as attractive features for AstraZeneca's acquisition target. The combined entity would have a more substantial scale, which could lead to further efficiency gains and increased competitiveness in the market.

Eli Lilly's massive $1 trillion valuation has put pressure on other pharmaceutical companies, such as Merck, to pursue deals ahead of looming patent cliffs. This consolidation trend is expected to reshape the industry landscape.